This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2016 by University Health Network, Toronto
Ozmosis Research Inc.
Information provided by (Responsible Party):
University Health Network, Toronto Identifier:
First received: September 25, 2014
Last updated: June 21, 2016
Last verified: June 2016

The purpose of this study is to find out how to increase the potential for achieving an "operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which a person does not require further treatment, although there may be some remaining cancer cells. Patients would normally remain on a TK inhibitor indefinitely within a standard of care setting for chronic myeloid leukemia. Within this clinical trial, patients will discontinue their TK inhibitor prematurely. If any signs of progression are identified, dasatinib will be introduced.

This research is being done because dasatinib has been shown to achieve a greater response in a much higher proportion of patients as compared to imatinib. Dasatinib is approximately 300 times more potent than imatinib, and it is possible that a greater response can be achieved by dasatinib than by imatinib.

Condition Intervention Phase
Chronic Myeloid Leukemia Drug: Dasatinib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Molecular Remission [ Time Frame: change from baseline in Molecular Profile at 12 months ]

Estimated Enrollment: 135
Study Start Date: October 2014
Estimated Study Completion Date: October 2021
Estimated Primary Completion Date: October 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions

This research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib.

Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years.

If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years.

If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib.

Drug: Dasatinib
Other Name: Sprycel

Detailed Description:

This is an open label, single arm Phase II trial that will examine how safe and effective it will be for patients with chronic myeloid leukemia (CML) to discontinued first line tyrosine kinase inhibitor (TKI) therapy.

The main goal of this study is to determine the potential role of dasatinib (the study drug) in helping patients with CML attain a sustained treatment free remission.

During this study the safety and tolerability of Dasatinib will be evaluated by means of drug related toxicity, adverse event reports, physical examinations and laboratory safety evaluations.

The study period for an individual patient is expected to be approximately between 30-72 months.

A total of 135 patients will be recruited from 10 Canadian centres.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of CML
  2. Treatment of chronic phase CML treated for a minimum of three years exclusively with imatinib
  3. Levels of BCR-ABL by RQ-PCR with ≥ 4.5 log reduction from baseline
  4. Provide written informed consent
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  6. Age >18 years.
  7. Adequate organ liver and renal functions
  8. Normal serum levels (within normal limits)

Exclusion Criteria:

  1. Prior treatment with a TKI (except for imatinib, hydroxyurea, anagrelide or interferon)
  2. Taking any medications or substances known to affect CYP3A4.
  3. Concurrent medical condition which may increase the risk of toxicity
  4. History of significant bleeding disorder unrelated to cancer
  5. Cardiac Symptoms
  6. Clinically significant hypokalemia or hypomagnesemia that cannot be corrected prior to dasatinib administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02268370

Contact: Sima Bogomilsky, RN BSN 416-946-4646

Canada, Alberta
Tom Baker Cancer Center Recruiting
Calgary, Alberta, Canada
Contact: Donna Forrest, M.D.         
University of Alberta Hospital Not yet recruiting
Edmonton, Alberta, Canada
Contact: Elena Liew, M.D.         
Canada, British Columbia
Vancouver General Hospital Recruiting
Vancouver, British Columbia, Canada, V5Z1M9
Contact: Donna Forrest, MD         
Canada, Manitoba
Cancer Care Manitoba Not yet recruiting
Winnipeg, Manitoba, Canada
Contact: Kristjan Paulson, M.D.         
Canada, Nova Scotia
Queen Elizabeth II Health Sciences Centre Recruiting
Halifax, Nova Scotia, Canada
Contact: Stephen Couban, M.D.         
Canada, Ontario
Juravinski Cancer Centre Recruiting
Hamilton, Ontario, Canada
Contact: Brian Leber, M.D.         
London Health Sciences Centre Recruiting
London, Ontario, Canada
Contact: Anagyros Xenocostas, M.D.         
Ottawa General Hospital Recruiting
Ottawa, Ontario, Canada
Contact: Isabelle Bence-Bruckler, M.D.         
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Jeffrey Lipton, M.D.         
Canada, Quebec
Centre Hôpitallier Universitaire de Quebec - Hôpital de l'Enfant-Jésus Recruiting
Charlesbourg, Quebec, Canada
Contact: Robert Delage, M.D.         
Hopital Maisonneuve-Rosemont Recruiting
Montreal, Quebec, Canada
Contact: Lambert Busque, M.D.         
McGill University Health Centre Not yet recruiting
Montreal, Quebec, Canada
Contact: Pierre Laneuville, M.D.         
Sponsors and Collaborators
University Health Network, Toronto
Ozmosis Research Inc.
Principal Investigator: Dennis Kim, MD University Health Network, Toronto
  More Information

Responsible Party: University Health Network, Toronto Identifier: NCT02268370     History of Changes
Other Study ID Numbers: BMS CA180-543
OZM-056 ( Other Identifier: Ozmosis Research Inc. )
Study First Received: September 25, 2014
Last Updated: June 21, 2016

Additional relevant MeSH terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017